Table 4.
Food and Drug Administration (FDA)-approved next-generation sequencing (NGS)-based methods suitable for cancer predisposition identification, cancer detection, or follow-up.
| Tradename | Description | Year | Target | Tumor | Utility |
|---|---|---|---|---|---|
| Illumina MiSeqDX platform | High throughput DNA sequence analyzer | 2013 | - | - | technology |
| FoundationFocus CDxBRCA | NGS oncology panel, somatic or germline variant detection system | 2016 | BRCA | ovarian | diagnosis |
| MSK-IMPACT | NGS-based tumor profiling test | 2017 | 468 genes | various | predisposition, diagnosis |
| FoundationOne CDx | NGS oncology panel, somatic or germline variant detection system | 2017 | 324 genes | various | predisposition, diagnosis |
| Oncomine Dx Target Test | NGS oncology panel, somatic or germline variant detection system | 2017 | 24 genes | lung | diagnosis |
| Praxis Extended RAS Panel | NGS oncology panel, somatic or germline variant detection system | 2017 | RAS | colon | diagnosis |
| Adaptive Biotechnologies clonoSEQ | DNA-based test for minimal residual disease for hematologic malignancies | 2018 | BCL1, BCL2 | leukemia, myeloma | follow-up |